Articles tagged with Drug Studies
Several studies have shown that reducing LDL-C to levels lower than 50 mg/dl can provide cardiovascular benefits. However, data on the impact of lowering LDL-C below 25 mg/dl is limited, with some evidence suggesting no increased risk of cancer or hemorrhagic stroke.
Research reveals flavonoids as potent P-gp modulators with high binding affinity and low toxicity, offering a new generation of drug candidates to reverse multidrug resistance. Synthetic flavonoid dimer FD18 specifically targets the pseudodimeric structure of the drug transporter.
A new study analyzed combined results of 47 randomized clinical trials, lasting at least 12 months, involving 22,000 patients with knee osteoarthritis. The research found uncertainty around long-term effectiveness of medications in controlling pain, highlighting the need for large randomized clinical trials.
Case Western Reserve University researcher Sanjay Gupta has been awarded nearly $1 million to investigate drug resistance mechanisms in prostate cancer. He will test two promising medications, simvastatin and metformin, to overcome drug resistance and halt metastasis.
Chemical synthesis breakthrough offers hope in combating lethal drug-resistant infections; researchers develop efficient, scaleable antibiotics to fight Staphylococcus aureus and other bacterial species.
Researchers discovered two tri-terpenoids, ursolic acid and lupeol, with potential activity against Alzheimer's disease pathology. Lupeol showed better binding affinity than ursolic acid, suggesting its potential as a BACE1 inhibitor for AD therapy.
Aerobic exercise shows promise in improving cognitive function and reducing weight gain in schizophrenia patients. Researchers are enrolling over 200 participants to test the effects of aerobic exercise versus a control group.
A phase three clinical trial found that sorafenib stopped progression of desmoid tumors for two years in 80 percent of patients who completed treatment. This is a significant increase in progression-free survival compared to placebo, with researchers describing it as 'a truly remarkable outcome'.
A first-in-human clinical trial found sutimlimab to be effective in treating severe hemolytic anemia in cold agglutinin disease. The investigational drug rapidly halted red blood cell destruction, increased hemoglobin levels, and eliminated the need for blood transfusions.
A new study in the Journal of Neuromuscular Diseases describes the use of a child-compatible, hand-held device to assess pulmonary function in teens with DMD. The results show that weekly use of the device was well accepted by participants, with high adherence rates and reliable data compared to standard spirometry.
A daily dose of buprenorphine-naloxone is cost-effective compared to monthly injections of extended-release naltrexone, with similar effectiveness in quality of life and time abstaining from opioids. The researchers conclude that buprenorphine-naloxone should be preferred as the first-line treatment for opioid use disorder.
A phase 2 trial found that an oral spray containing THC-CBD reduced spasticity in adults with motor neuron disease, improving muscle tone and pain levels. The treatment was well-tolerated and showed promise as a potential option for managing symptoms.
A study of 100 patients found that linking medication reminders to electronic health records (EHRs) improved adherence among glaucoma patients. The reminders were delivered via text or voice message for three months and were reported useful by 74% of participants.
A study at Duke University Medical Center found that weekly whole-body massage improved symptoms of knee osteoarthritis, including pain and mobility, in patients. The treatment maintained its benefits over 52 weeks, suggesting a potential complement to existing treatments.
Researchers found that haloperidol did not benefit elective thoracic surgery ICU patients when given prophylactically, except in those who had undergone esophagectomy. The study suggests a need for a personalized approach to delirium prevention and treatment, focusing on high-risk patients.
A Vanderbilt University Medical Center study found that high-dose antipsychotic medications increase the risk of unexpected death in children and young adults. The study analyzed data from over 250,000 children and young people aged 5-24, revealing a 3.5-fold increased risk of unexpected death compared to those taking lower doses.
A study of 250,000 children aged 5-24 found that those taking higher doses of antipsychotics were at a higher risk of dying from unintentional overdose or cardiovascular causes. The findings highlight the need for careful prescribing and monitoring of these medications in young people.
Researchers compared the Nike Vaporfly 4% with traditional track spikes, finding that the shoe reduces oxygen update rates and improves performance by 4.2%. The study suggests that lighter running shoes like the NVF can propel athletes forward more efficiently.
Researchers aim to evaluate a low dose blood-thinning medication for people with advanced kidney disease, a condition affecting over 30.5 million globally. The five-year trial will also investigate the safety of this medication in reducing heart attacks, strokes and deaths.
Researchers at the University of Iowa used a multidisciplinary approach to identify 90 FDA-approved drugs that may have potential as anti-seizure treatments. Gene expression profiling and bioinformatics revealed that these drugs significantly reduced seizures in zebrafish models.
A new review of 28 scientific studies substantiates that changes in diet, prescription medications, and physical activity reduce food cravings. Losing weight and avoiding frequent eating of certain foods are proven strategies to manage cravings.
A large study found that taking metformin reduced weekly pregnancy weight gain, but did not improve other pregnancy outcomes. The research supports the need for pre-pregnancy dietary and lifestyle interventions to break the cycle of intergenerational obesity.
A phase 2 trial of 70 men with cannabis dependence or use disorder found that an experimental drug reduced cannabis use and withdrawal symptoms compared to placebo. The drug, PF-04457845, works by blocking an enzyme that breaks down a natural endocannabinoid chemical in the brain.
A recent study published in The Lancet found that fluoxetine, a common antidepressant, does not improve physical ability or reduce disability after stroke. However, researchers did note a small increase in bone fractures among those taking the medication.
A large Nordic study found liraglutide reduces the risk of myocardial infarction, stroke, or cardiovascular death among type 2 diabetes patients. The study also showed a lower risk of cardiovascular death and any cause of death with liraglutide treatment.
The combination of ibrutinib plus rituximab was superior to standard treatment in improving progression-free survival and overall survival for patients with chronic lymphocytic leukemia. The treatment also showed fewer serious side effects compared to the standard FCR regimen.
Medication administration errors are a significant concern, with omissions being the most common cause, particularly among elderly patients. The study highlights the need for vigilant attention to safe dosing practices, especially in older adults.
A study found that older adults with heart failure who take five or more medications are at higher risk for cognitive impairment and difficulty performing daily activities. The researchers suggest that healthcare providers should consider these limitations when prescribing medications, as they may unnecessarily expose patients to incre...
A randomized trial of over 3000 participants found that sharing personalized ultrasound scan images reduces cardiovascular disease risk. The study showed improved outcomes in smoking cessation, physical activity, statins, and antihypertensive medication.
A new combination therapy involving ipilimumab, nivolumab, and brentuximab vedotin safely reduces tumor size or spread in 95% of patients with recurrent Hodgkin lymphoma, achieving complete remission in 16 patients.
A new randomised trial found that sharing pictorial representations of personalised scans showing the extent of atherosclerosis reduced cardiovascular disease risk one year later. The study showed improvements in total and LDL cholesterol levels, with the strongest effect seen for those at highest risk.
A follow-up analysis of axi-cel-treated patients with diffuse large B-cell lymphoma (DLBCL) reported that 51% were still alive two years post-treatment. The study found that 83% achieved a reduction in cancer activity, and 39% had ongoing responses. CAR-T cell persistence and B-cell recovery were also observed in most patients.
Researchers at Dana-Farber Cancer Institute present positive results from clinical trials of CAR T-cell therapy and immunotherapy for patients with leukemia and lymphoma. The studies show that Yescarta provides durable benefit to lymphoma patients, while pembrolizumab achieves long-lasting responses in patients with an aggressive form ...
The phase-2 JULIET trial found that CAR-T cell therapy achieved a 52% favorable response rate in patients with relapsed or refractory diffuse large B-cell lymphoma, with 40% experiencing complete responses. Sixty-five percent of patients remained relapse-free after one year.
A global clinical trial has shown that chimeric antigen receptor (CAR) T cell therapy can lead to long-lasting remissions in patients with relapsed/refractory diffuse large B-cell lymphoma. The treatment, known as Kymriah, modified patients' own immune T cells to target cancer cells and achieved high remission rates.
Researchers have developed an effective monoclonal antibody treatment, lanadelumab, that can reduce the frequency of life-threatening swelling attacks in patients with hereditary angioedema. The treatment has shown a 90% reduction in attack rate and can be self-administered every two weeks.
A new combination treatment of venetoclax and azacitidine has shown a 91 percent response rate in older adults with newly diagnosed acute myeloid leukemia (AML). The treatment has been associated with no more side effects than the use of azacitidine alone, and patients with IDH mutations have experienced long-lasting responses.
A randomized, controlled trial is enrolling patients with confirmed Ebola virus disease in the Democratic Republic of Congo to compare mortality among those receiving three investigational drugs with a control group. The trial aims to establish the safety and efficacy of these treatments in a comprehensive response to combat Ebola.
A Phase 3 clinical trial shows that lanadelumab injections significantly reduce the number of hereditary angioedema attacks, with improvements in quality of life. The treatment also outperforms placebo in reducing attack frequency and severity.
A new study by McGill University researchers suggests that clinical trials may promote the use of ineffective and costly treatments, particularly with blockbuster pain drug pregabalin. The researchers found that despite strong evidence supporting pregabalin's effectiveness for certain conditions, many studies failed to conduct rigorous...
A neuroimaging study reveals that the medial prefrontal cortex (mPFC) shows increased activity when patients are shown drug cues, indicating a potential target for addiction treatment. The study aims to develop a novel non-invasive therapy using transcranial magnetic stimulation (TMS) to modulate neural networks.
Researchers developed a new oral immunotherapy drug, AR101, derived from peanut protein, to build tolerance in peanut allergy sufferers. The study found that more than two-thirds of participants taking the active drug could tolerate a dose of peanut protein equivalent to about two peanut kernels.
A clinical trial found that aspirin reduced the number of polyps overall, including on the right side, while EPA reduced polyps on the left side. Both compounds had preventative effects by reducing specific types of polyps.
A new study found that only about a third of mandatory pediatric post-marketing drug studies were completed within seven years, leading to a lack of child-specific information on medication labels. This perpetuates off-label prescribing that may be unsafe or ineffective for children.
A Kansas State University researcher is studying the impact of sex hormones on trauma survival in both men and women. She aims to identify differences in response to medication and surgery after traumatic events and develop more effective treatments.
A new study finds that CP201, a nerve-cell-protecting snippet of ADNP protein, normalizes disrupted neural connectivity and improves vocal communication in ADNP-deficient mice. The research paves the way for a clinical trial to treat social, motor, and vocal communication impediments in ADNP syndrome patients.
A new study by RCSI found that older hospital patients are 72% more likely to receive inappropriate prescriptions, regardless of other factors. The research highlights the need for healthcare providers to consider the potential adverse effects of hospitalization on prescribing appropriate medication for older adults.
A new study found that social media users who view alcohol ads are more likely to 'Like' or 'Share' an ad when it has pro-drinking comments. The researchers suggest that the industry needs to improve its self-regulatory system to limit or ban comments on social media advertising.
Researchers at MD Anderson Cancer Center report high response rates of 90% among frontline-treated patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The study, led by Naveen Pemmaraju, presents a novel targeted therapy targeting CD-123, a cell surface receptor expressed in BPDCN and other hematologic malignancies.
Two studies found that fewer than 25% of California retail pharmacies dispense naloxone without a physician's prescription, and 69% of Texas chain pharmacies reported having the medication in stock. The studies aimed to assess naloxone accessibility after legislation allowed pharmacists to provide the antidote without a prescription.
The Infectious Diseases Society of America (IDSA) has released new guidelines for outpatient parenteral antimicrobial therapy (OPAT), emphasizing the importance of review by an infectious diseases specialist before starting treatment. Regular monitoring and blood tests are also recommended to ensure patient safety.
A study led by St. Michael's Hospital researchers found that empagliflozin significantly reduces left ventricular mass index, a key indicator of heart disease. The medication has profound cardiovascular benefits, including improved cardiac structure and reduced mortality rates in people with Type 2 diabetes and heart disease.
Researchers have found a new therapeutic target for pancreatic cancer, RIP1 Kinase, which can be used in combination with other immune-boosting therapies to increase survival rates. The study shows that the drug GSK547 helps to mount a more aggressive attack against tumor cells, doubling survival to 50 days in mice.
A study on UK dairy farm medicines storage practices found most farmers store medicines appropriately, but with room for improvement. Inappropriate use and disposal of expired medicines are common, highlighting the need for open conversations between veterinarians and farmers.
Researchers presented a phase 2 trial showing capivasertib's potential in treating various types of cancer with the AKT mutation. The treatment resulted in tumor shrinkage in 23% of patients and prolonged time without tumor growth for 52%.
A Yale-led research study found that a drug therapy used for chronic heart failure also improves markers of poor prognosis in individuals hospitalized with acute heart failure. The treatment reduced NT-proBNP levels more quickly than standard therapy, indicating substantial improvement in heart failure severity.
A new study of over 174,000 patients found that being treated with too much medication for hypothyroidism can lead to an increased risk of atrial fibrillation and stroke. The research suggests that the optimal healthy range of free thyroxine (fT4) levels may need to be reconsidered.
The REDUCE-IT trial found that icosapent ethyl reduced the risk of death due to cardiovascular causes, heart attack, and stroke by 25%, including a 20% reduction in death and 31% reduction in heart attack. This may set a new standard for patients with elevated triglycerides and increased cardiovascular risk despite statin therapy.
The Dapagliflozin Effect on CardiovascuLAR Events - Thrombolysis in Myocardial Infarction 58 trial found that dapagliflozin markedly reduced the risk of hospitalization for heart failure and progression of renal disease, with benefits seen across the study population.
A recent trial found that low-dose methotrexate did not lower cardiovascular event rates in patients at high risk for heart disease and stroke. The study, which included over 4,700 participants, showed no significant reduction in major adverse cardiovascular events compared to placebo.